Market Closed -
Other stock markets
|
After market 16:01:14 | |||
23.6 EUR | +0.43% |
|
23.58 | -0.06% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company appears to be poorly valued given its net asset value.
- This company will be of major interest to investors in search of a high dividend stock.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- The opinion of analysts covering the stock has improved over the past four months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- One of the major weak points of the company is its financial situation.
- With an expected P/E ratio at 45.24 and 69.41 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-9.23% | 39.97B | - | ||
+51.99% | 803B | C+ | ||
-5.72% | 351B | C+ | ||
+18.94% | 324B | B- | ||
+11.07% | 303B | C+ | ||
+16.96% | 243B | B+ | ||
+2.25% | 228B | A+ | ||
+11.15% | 217B | B- | ||
+7.59% | 164B | C+ | ||
-3.65% | 155B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 4502 Stock
- TKD Stock
- Ratings Takeda Pharmaceutical Company Limited